HCM
BDTX icon

Hawkeye Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Hawkeye Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-243,009
Closed -$598K – 29
2022
Q2 		$598K Hold
243,009
– – 0.33% 27
2022
Q1 		$673K Buy
243,009
+93,009
+62% +$340K 0.27% 29
2021
Q4 		$800K Buy
+150,000
New +$1.05M 0.32% 35

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hawkeye Capital Management's BDTX Position: Q3 2022 in Review

Hawkeye Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2022, closing a stake of 243,009 shares — an estimated $598K sold.

Hawkeye Capital Management first reported a position in BDTX in Q4 2021 and held it in 3 quarters. The position peaked at $800K in Q4 2021. 69 funds tracked by Wall St. Rank hold BDTX as of Q3 2022.

  • Hawkeye Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Hawkeye Capital Management sold 243,009 Black Diamond Therapeutics shares in Q3 2022, an estimated $598K.
  • Hawkeye Capital Management first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 3 quarters.
  • Hawkeye Capital Management's Black Diamond Therapeutics position peaked at $800K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2022.

Based on Hawkeye Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.